Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• HidalgoMPancreatic cancerN Engl J Med2010362171605161720427809
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156
   PubMed Web of Science ®Google Scholar
• OettleHRiessHStielerJMSecond-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trialJ Clin Oncol201432232423242924982456
   PubMed Web of Science ®Google Scholar
• UenoHOkusakaTFunakoshiAA phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancerCancer Chemother Pharmacol200759444745416855842
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• ZaniboniAAitiniEBarniSFOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II studyCancer Chemother Pharmacol20126961641164522576338
   PubMed Web of Science ®Google Scholar
• NeuzilletCHenticORousseauBFOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-saltsWorld J Gastroenterol201218334533454122969226
   PubMed Web of Science ®Google Scholar
• TakaharaNNakaiYIsayamaHUridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancerCancer Chemother Pharmacol2013711859223053265
   PubMed Web of Science ®Google Scholar
• SasakiTIsayamaHNakaiYCurrent status of chemotherapy for the treatment of advanced biliary tract cancerKorean J Intern Med201328551552424009445
   PubMed Web of Science ®Google Scholar
• CeredaSBelliCRognoneASecond-line therapy in advanced biliary tract cancer: what should be the standard?Crit Rev Oncol Hematol201388236837423786845
   PubMed Web of Science ®Google Scholar
• ValleJWasanHPalmerDHCisplatin plus gemcitabine versus gemcitabine for biliary tract cancerN Engl J Med2010362141273128120375404
   PubMed Web of Science ®Google Scholar
• SasakiTIsayamaHNakaiYA pilot study of salvage irinotecan monotherapy for advanced biliary tract cancerAnticancer Res20133362619262223749917
   PubMed Web of Science ®Google Scholar
• MorettoRRaimondoLDe StefanoAFOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experienceAnticancer Drugs201324998098523928570
   PubMed Web of Science ®Google Scholar
• O’DwyerPJCatalanoRBUridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapyJ Clin Oncol200624284534453817008691
   PubMed Web of Science ®Google Scholar
• DesaiAAInnocentiFRatainMJPharmacogenomics: road to anticancer therapeutics nirvana?Oncogene200322426621662814528287
   PubMed Web of Science ®Google Scholar
• SharmaMCatenacciDVTKarrisonTA UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignanciesJ Clin Oncol201432Suppl abstr 4125
   Google Scholar
• InnocentiFKroetzDLSchuetzEComprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsJ Clin Oncol200927162604261419349540
   PubMed Web of Science ®Google Scholar
• ZhouCFMaTSuYUGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancerAnticancer Agents Med Chem201313223524122934695
   PubMed Web of Science ®Google Scholar
• GaoJZhouJLiYAssociations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patientsMed Oncol201330363023783485
   PubMed Web of Science ®Google Scholar
• GaoJZhouJLiYUGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patientsMed Oncol201330360423686699
   PubMed Web of Science ®Google Scholar
• NagarSBlanchardRLPharmacogenetics of uridine diphosphoglucuronosyl transferase (UGT) 1A family members and its role in patient response to irinotecanDrug Metab Rev200638339340916877259
   PubMed Web of Science ®Google Scholar
• OkuyamaYHazamaSNozawaHProspective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphismsJpn J Clin Oncol201141447748221303789
   PubMed Web of Science ®Google Scholar
• PremawardhenaAFisherCALiuYTThe global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implicationsBlood Cells Mol Dis20033119810112850492
   PubMed Web of Science ®Google Scholar
• JadaSRLimRWongCIRole of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patientsCancer Sci20079891461146717627617
   PubMed Web of Science ®Google Scholar
• HuZYYuQZhaoYSDose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysisEur J Cancer201046101856186520335017
   PubMed Web of Science ®Google Scholar
• InnocentiFUndeviaSDIyerLGenetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia ofirinotecanJ Clin Oncol20042281382138815007088
   PubMed Web of Science ®Google Scholar
• HanJYLimHSShinESComprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatinJ Clin Oncol200624152237224416636344
   PubMed Web of Science ®Google Scholar
• MarshSHoskinsJMIrinotecan pharmacogenomicsPharmacogenomics20101171003101020602618
   PubMed Web of Science ®Google Scholar